Sensus Healthcare, Inc. SRTS
Sensus Healthcare, Inc. (SRTS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $27.5M at a -28.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.64 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.776 |
| Retained earnings / assets | 0.108 |
| EBIT / assets | -0.194 |
| Equity / liabilities | 9.734 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SRTS | Sensus Healthcare, Inc. | 4/9 | 14.36 | — | -34.3% |
| SSKN | STRATA Skin Sciences, Inc. | 4/9 | — | — | -8.5% |
| BDMD | Baird Medical Investment Holdings Ltd | 1/9 | 0.49 | — | -39.2% |
| DRIO | DarioHealth Corp. | 3/9 | -12.4 | — | -17.3% |
| OBIO | Orchestra BioMed Holdings, Inc. | 5/9 | -7.02 | — | — |
| MDAI | Spectral AI, Inc. | 3/9 | -11.78 | — | -33.6% |
| SNOA | Sonoma Pharmaceuticals, Inc. | 2/9 | — | — | +36.7% |
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos, as well as provide operational healthcare services for dermatology clinics. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.
FAQ
Is SRTS financially healthy?
Sensus Healthcare, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does SRTS pay a dividend?
No, Sensus Healthcare, Inc. does not currently pay a dividend.
How profitable is SRTS?
In FY2025, Sensus Healthcare, Inc. had a net margin of -28.1% and a return on equity of -16.0%.
Is SRTS overvalued or undervalued?
Sensus Healthcare, Inc. trades at about 7.6× trailing earnings — below its 10-year norm (10-year range 6.3×–108.3×, median 30.8×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for SRTS?
The average Wall-Street price target for Sensus Healthcare, Inc. is $5.75, about 83.7% above the recent price, from 4 analysts.
Is SRTS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Sensus Healthcare, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.